Brownet al. argue that epigenetic heterogeneity leads to therapeutic resistance, such that bivalently marked gene promoters result in epigenetically poised gene expression that can become fixed by exposure to therapy. What are the opportunities to target this proposed mechanism of therapeutic resistance?
- Robert Brown
- Edward Curry
- Jane Borley
